Acqaviva B, Cayla J, Delcambre B, Le Goff P, Loyau G, Serratrice G, Ziegler G
Sem Hop. 1983 Dec 12;59(46):3229-34.
The effectiveness and tolerance of Bi-Profenid as 150 mg tablets were analyzed in a multicenter study. Each of the 288 patients entered in the study had one of the main conditions found in rheumatologic practice: arthrosis of the hip or knee, rheumatoid arthritis or ankylosing spondylarthritis. Each patient was given one 150 mg Bi-Profenid tablet twice daily for 30 days. Overall effectiveness, as assessed by the pain scale test, produced improvement in 87.3% of cases. In degenerative rheumatic diseases, nocturnal pain, pain upon mobilization and walking distance were very significantly improved. In inflammatory rheumatic diseases, the significantly improved parameters were nocturnal pain, morning stiffness and functional indexes of rheumatoid arthritis. Tolerance was outstanding or very good in 77.1% of cases and the dropout rate was only 7.6%.
在一项多中心研究中分析了150毫克片剂必洛芬的有效性和耐受性。参与该研究的288名患者每人都患有风湿病实践中常见的主要病症之一：髋或膝关节骨关节炎、类风湿性关节炎或强直性脊柱炎。每位患者每天服用两片150毫克必洛芬片剂，持续30天。通过疼痛量表测试评估，总体有效率为87.3%。在退行性风湿性疾病中，夜间疼痛、活动时疼痛和步行距离都有非常显著的改善。在炎性风湿性疾病中，显著改善的参数是夜间疼痛、晨僵和类风湿性关节炎的功能指标。77.1%的病例耐受性出色或非常好，脱落率仅为7.6%。
